Skip to main content
Advertisement

Main menu

  • Home
  • Content
    • Current Issue
    • Publication Preview--Ahead of Print
    • Past Issue Archive
    • Case of the Week Archive
    • Classic Case Archive
    • Case of the Month Archive
    • COVID-19 Content and Resources
  • For Authors
  • About Us
    • About AJNR
    • Editors
    • American Society of Neuroradiology
  • Submit a Manuscript
  • Podcasts
    • Subscribe on iTunes
    • Subscribe on Stitcher
  • More
    • Subscribers
    • Permissions
    • Advertisers
    • Alerts
    • Feedback
  • Other Publications
    • ajnr

User menu

  • Subscribe
  • Alerts
  • Log in

Search

  • Advanced search
American Journal of Neuroradiology
American Journal of Neuroradiology

American Journal of Neuroradiology

  • Subscribe
  • Alerts
  • Log in

Advanced Search

  • Home
  • Content
    • Current Issue
    • Publication Preview--Ahead of Print
    • Past Issue Archive
    • Case of the Week Archive
    • Classic Case Archive
    • Case of the Month Archive
    • COVID-19 Content and Resources
  • For Authors
  • About Us
    • About AJNR
    • Editors
    • American Society of Neuroradiology
  • Submit a Manuscript
  • Podcasts
    • Subscribe on iTunes
    • Subscribe on Stitcher
  • More
    • Subscribers
    • Permissions
    • Advertisers
    • Alerts
    • Feedback
  • Follow AJNR on Twitter
  • Visit AJNR on Facebook
  • Follow AJNR on Instagram
  • Join AJNR on LinkedIn
  • RSS Feeds
Abstract

Phase III multicenter trial of high-dose gadoteridol in MR evaluation of brain metastases.

W T Yuh, D J Fisher, V M Runge, S W Atlas, S E Harms, K R Maravilla, N A Mayr, J E Mollman and A C Price
American Journal of Neuroradiology June 1994, 15 (6) 1037-1051;
W T Yuh
Department of Radiology, University of Iowa College of Medicine, Iowa City.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D J Fisher
Department of Radiology, University of Iowa College of Medicine, Iowa City.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
V M Runge
Department of Radiology, University of Iowa College of Medicine, Iowa City.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S W Atlas
Department of Radiology, University of Iowa College of Medicine, Iowa City.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S E Harms
Department of Radiology, University of Iowa College of Medicine, Iowa City.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
K R Maravilla
Department of Radiology, University of Iowa College of Medicine, Iowa City.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
N A Mayr
Department of Radiology, University of Iowa College of Medicine, Iowa City.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J E Mollman
Department of Radiology, University of Iowa College of Medicine, Iowa City.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A C Price
Department of Radiology, University of Iowa College of Medicine, Iowa City.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

PURPOSE To assess the efficacy and safety profile of high-dose (0.3 mmol/kg cumulative dose) gadoteridol in patients with suspected central nervous system metastatic disease.

METHODS We studied 67 patients using an incremental-dose technique. Patient monitoring included a medical history, physical examination, vital signs, and extensive laboratory tests within 24 hours before and after the MR examination. Precontrast T1- and T2-weighted spin-echo studies were performed, followed by intravenous injection of 0.1 mmol/kg of gadoteridol. T1-weighted images were acquired immediately after and at 10 and 20 minutes after injection. At 30 minutes an additional 0.2 mmol/kg of gadoteridol was administered (0.3-mmol/kg cumulative dose), and T1-weighted images were acquired. Cases demonstrating abnormal MR findings were assessed for efficacy by unblinded and blinded reviewers and were analyzed quantitatively.

RESULTS Three adverse effects in two patients were considered to be related to gadoteridol administration. No adverse effects were serious; all self-resolved. Forty-nine cases showed abnormal MR findings and were included in the efficacy analysis. A significantly greater number of lesions was seen on the high-dose as opposed to the standard-dose images. Blinded and unblinded readers identified 5 and 8 patients, respectively, with solitary lesions on standard-dose examination and multiple lesions on high-dose examination. Two patients who had normal standard-dose findings had lesions identified on high-dose studies. Quantitative analysis of 133 lesions in 45 patients demonstrated significant increases in lesion signal intensity on high-dose studies when compared with standard-dose studies.

CONCLUSION Gadoteridol can be safely administered up to a cumulative dose of 0.3 mmol/kg. High-dose contrast studies provide improved lesion detectability and additional diagnostic information over studies performed in the same patients with a 0.1-mmol/kg dose and aid in patient diagnosis and treatment. High-dose gadoteridol study may facilitate the care of patients with suspected central nervous system metastasis.

  • Copyright © American Society of Neuroradiology
PreviousNext
Back to top

In this issue

American Journal of Neuroradiology
Vol. 15, Issue 6
1 Jun 1994
  • Table of Contents
  • Index by author
Advertisement
Download PDF
Email Article

Thank you for your interest in spreading the word on American Journal of Neuroradiology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Phase III multicenter trial of high-dose gadoteridol in MR evaluation of brain metastases.
(Your Name) has sent you a message from American Journal of Neuroradiology
(Your Name) thought you would like to see the American Journal of Neuroradiology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Phase III multicenter trial of high-dose gadoteridol in MR evaluation of brain metastases.
W T Yuh, D J Fisher, V M Runge, S W Atlas, S E Harms, K R Maravilla, N A Mayr, J E Mollman, A C Price
American Journal of Neuroradiology Jun 1994, 15 (6) 1037-1051;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Phase III multicenter trial of high-dose gadoteridol in MR evaluation of brain metastases.
W T Yuh, D J Fisher, V M Runge, S W Atlas, S E Harms, K R Maravilla, N A Mayr, J E Mollman, A C Price
American Journal of Neuroradiology Jun 1994, 15 (6) 1037-1051;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Delineation of brain metastases on CT images for planning radiosurgery: concerns regarding accuracy
  • MR Contrast Media in Neuroimaging: A Critical Review of the Literature
  • Crossref
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

Similar Articles

Advertisement

News and Updates

  • Lucien Levy Best Research Article Award
  • Thanks to our 2022 Distinguished Reviewers
  • Press Releases

Resources

  • Evidence-Based Medicine Level Guide
  • How to Participate in a Tweet Chat
  • AJNR Podcast Archive
  • Ideas for Publicizing Your Research
  • Librarian Resources
  • Terms and Conditions

Opportunities

  • Share Your Art in Perspectives
  • Get Peer Review Credit from Publons
  • Moderate a Tweet Chat

American Society of Neuroradiology

  • Neurographics
  • ASNR Annual Meeting
  • Fellowship Portal
  • Position Statements

© 2023 by the American Society of Neuroradiology | Print ISSN: 0195-6108 Online ISSN: 1936-959X

Powered by HighWire